Ledipasvir D-tartrate

• CAT Number: I001857
• CAS Number: 1502654-87-6
• Molecular Formula: C53H60F2N8O12
• Molecular Weight: 1039.09
• Purity: ≥95%
• Target: HCV
• Solubility: DMSO: ≥ 28 mg/mL
• Storage: Store at -20C
• IC50: 141 nM (EC50, JFH1/3a-NS5A hybrid replicon)
• IUPAC Name: (2S,3S)-2,3-dihydroxybutanedioic acid;methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
• InChI: InChI=1S/C49H54F2N8O6.C4H6O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6;5-1(3(7)8)2(6)4(9)10/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63);1-2,5-6H,(H,7,8)(H,9,10)/t29-,30+,38-,39-,40-,41-;1-,2-/m00/s1
• InChIKey: ZQVLPYMRXLPMDX-KEAIDYLOSA-N
• SMILES: CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O

Ledipasvir D-Tartrate（Cat No.:I001857）is a high-purity antiviral compound used in hepatitis C virus (HCV) research. It inhibits the HCV NS5A protein, a critical factor in viral replication and assembly, effectively disrupting the viral life cycle. The D-tartrate form enhances its solubility and stability, making it suitable for experimental and preclinical studies. Ledipasvir D-Tartrate is widely studied for its role in combination therapies, offering insights into mechanisms of action and resistance in HCV treatment. Its specificity and efficacy make it a valuable tool in advancing antiviral drug development.

Reference

[1]. Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013 May;57(1):13-8.
[2]. Lawitz EJ, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012 Jul;57(1):24-31.